Oncofertility Ovarian Salvage

Cyclophosphamide equivalent dose (CED) over 15 grams per meter squared puts pediatric patients at high risk for ovarian failure.

The patient's CED was 30.8 grams per meter squared, placing her at high risk for primary ovarian insufficiency.

Ovarian transposition may not provide adequate distance from scatter radiation in young patients receiving pelvic radiation.

GnRH agonist therapy has not demonstrated clear fertility preservation benefit in pediatric patients and is not recommended as first-line by ASCO.

GnRH agonist therapy may have some benefit in older patients with breast cancer, though studies conflict.

Ovarian tissue cryopreservation is experimental and followed by future ovarian tissue transplantation, allowing about 30% of patients to have fertility.

Most fertility data from ovarian tissue transplantation comes from post-pubertal patients, but studies show visible follicles in tissue from pediatric patients.

Ovarian tissue is typically cryopreserved within the same day of harvest to minimize egg loss from lack of vascular supply.

Orthotopic transplantation involves placing tissue back where the ovary was removed, either sewn to the contralateral ovary or in a peritoneal pocket near the fallopian tube.

Meta-analysis data shows 37-50% of patients with transplants had live births, with 30-40% achieving fertility preservation (some requiring multiple transplants).

60-90% of patients with ovarian tissue transplants achieve restoration of ovarian endocrine function.

Ovarian tissue cryopreservation requires both a surgeon to remove tissue and facilities to freeze it on-site.

Ovarian tissue cryopreservation became standard of care first in the Netherlands.

Sperm banking is only an option for post-pubertal males, typically Tanner stage 3 and above.

For prepubertal males receiving high-dose treatment, testicular tissue cryopreservation is available through protocols such as at University of Pittsburgh.

Testicular tissue preservation typically involves a wedge biopsy rather than full orchiectomy.

Ovarian tissue transplantation is typically performed only when pregnancy is desired because the graft lasts only 2-5 years.

Hormone replacement medication is used for pubertal induction and hormone support until pregnancy is desired.

Most centers now use long-term storage facilities with three or four mechanisms for detecting tank dysfunction to prevent tissue loss.

Hospital fees and anesthesia fees can often be covered by insurance when ovarian tissue harvest is combined with other oncology procedures like bone marrow biopsy or central line placement.

Tissue storage costs are income-dependent: $75 per year for oncology patients below income threshold, $275 per year above threshold.